To sum up, our results shows that trametinib significantly antagonizes ABCB1-mediated cancer MDR in vitro and in vivo by directly blocking the drug-efflux function of ABCB1, which is supported by the predicted binding mode that showed the hydrophobic interactions of trametinib within the large drug binding cavity of ABCB1. Here, ABCB1 is linked to cancer.